Self-Renewal of Single Mouse Hematopoietic Stem Cells Is Reduced by JAK2V617F Without Compromising Progenitor Cell Expansion

PLoS Biology

Volumn 11, Issue 6, 2013, Pages

  Kent, David G ^a,b   Li, Juan ^a,b   Tanna, Hinal ^a,b   Fink, Juergen ^a,b   Kirschner, Kristina ^a,b   Pask, Dean C ^a,b   Silber, Yvonne ^a,b   Hamilton, Tina L ^a,b   Sneade, Rachel ^a,b   Simons, Benjamin D ^b,c   Green, Anthony R ^a,b,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; DAUGHTER CELL; DISEASE COURSE; GENE MUTATION; HEMATOPOIETIC STEM CELL; HETEROZYGOSITY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PROGENY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE CELL ANALYSIS; STEM CELL EXPANSION; STEM CELL TRANSPLANTATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, CD; CELL COUNT; CELL CYCLE; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CLONE CELLS; GENE KNOCK-IN TECHNIQUES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; MICE; MUTATION; MYELOPROLIFERATIVE DISORDERS;

MUS;

EID: 84879396181     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001576     Document Type: Article

References (65)

1. Bryder D, Rossi DJ, Weissman IL, (2006) Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol 169: 338-346.
2. Simons BD, Clevers H, (2011) Strategies for homeostatic stem cell self-renewal in adult tissues. Cell 145: 851-862.
3. Nguyen LV, Vanner R, Dirks P, Eaves CJ, (2012) Cancer stem cells: an evolving concept. Nat Rev Cancer 12: 133-143.
4. Snippert HJ, van der Flier LG, Sato T, van Es JH, van den Born M, et al. (2010) Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 143: 134-144.
5. Clayton E, Doupe DP, Klein AM, Winton DJ, Simons BD, et al. (2007) A single type of progenitor cell maintains normal epidermis. Nature 446: 185-189.
6. Levine RL, Pardanani A, Tefferi A, Gilliland DG, (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7: 673-683.
7. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA, (2011) New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118: 1723-1735.
8. Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, et al. (2010) Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 18: 524-535.
9. Schaub FX, Jager R, Looser R, Hao-Shen H, Hermouet S, et al. (2009) Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood 113: 2022-2027.
10. Dupont S, Masse A, James C, Teyssandier I, Lecluse Y, et al. (2007) The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110: 1013-1021.
11. Kralovics R, Passamonti F, Teo SS, Buser AS, Tiedt R, et al. (2005) A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. New England Journal of Medicine 352: 1779-1790.
12. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148.
13. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397.
14. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061.
15. Li J, Kent DG, Chen E, Green AR, (2011) Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech 4: 311-317.
16. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 115: 3589-3597.
17. Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, et al. (2010) Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17: 584-596.
18. Marty C, Lacout C, Martin A, Hasan S, Jacquot S, et al. (2010) Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 116: 783-787.
19. Li J, Spensberger D, Ahn JS, Anand S, Beer PA, et al. (2010) JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 116: 1528-1538.
20. Dykstra B, Kent D, Bowie M, McCaffrey L, Hamilton M, et al. (2007) Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell 1: 218-229.
21. Sieburg HB, Cho RH, Dykstra B, Uchida N, Eaves CJ, et al. (2006) The hematopoietic stem compartment consists of a limited number of discrete stem cell subsets. Blood 107: 2311-2316.
22. Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Miura Y, et al. (1992) In vivo and in vitro stem cell function of c-kit- and Sca-1-positive murine hematopoietic cells. Blood 80: 3044-3050.
23. Osawa M, Nakamura K, Nishi N, Takahasi N, Tokuomoto Y, et al. (1996) In vivo self-renewal of c-Kit+ Sca-1+ Lin(low/-) hemopoietic stem cells. J Immunol 156: 3207-3214.
24. Kent DG, Copley MR, Benz C, Wohrer S, Dykstra BJ, et al. (2009) Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. Blood 113: 6342-6350.
25. Kent DG, Dykstra BJ, Cheyne J, Ma E, Eaves CJ, (2008) Steel factor coordinately regulates the molecular signature and biologic function of hematopoietic stem cells. Blood 112: 560-567.
26. Dykstra B, Olthof S, Schreuder J, Ritsema M, de Haan G, (2011) Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells. J Exp Med 208 (13):: 2691-2703.
27. Rossi DJ, Bryder D, Seita J, Nussenzweig A, Hoeijmakers J, et al. (2007) Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 447: 725-729.
28. Cho RH, Sieburg HB, Muller-Sieburg CE, (2008) A new mechanism for the aging of hematopoietic stem cells: aging changes the clonal composition of the stem cell compartment but not individual stem cells. Blood 111: 5553-5561.
29. Dykstra B, Ramunas J, Kent D, McCaffrey L, Szumsky E, et al. (2006) High-resolution video monitoring of hematopoietic stem cells cultured in single-cell arrays identifies new features of self-renewal. Proc Natl Acad Sci U S A 103: 8185-8190.
30. Zhang CC, Lodish HF, (2005) Murine hematopoietic stem cells change their surface phenotype during ex vivo expansion. Blood 105: 4314-4320.
31. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, et al. (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 131: 208-213.
32. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, et al. (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19: 1847-1849.
33. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, et al. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366: 1945-1953.
34. Strobbe L, Lestrade P, Hermans MH, Fijnheer R, (2007) Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause. Ann Hematol 86: 801-803.
35. Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, et al. (2012) Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F polycythemia vera. Blood 120 (1):: 166-172.
36. Skoda RC, (2010) JAK2 impairs stem cell function? Blood 116: 1392-1393.
37. Xu X, Zhang Q, Luo J, Xing S, Li Q, et al. (2007) JAK2(V617F): Prevalence in a large Chinese hospital population. Blood 109: 339-342.
38. Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL, (2008) Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol 36: 1480-1486.
39. Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, et al. (2006) The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A 103: 6224-6229.
40. James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, et al. (2008) The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood 112: 2429-2438.
41. Anand S, Stedham F, Beer P, Gudgin E, Ortmann CA, et al. (2011) Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood 118: 177-181.
42. Ishii T, Zhao Y, Sozer S, Shi J, Zhang W, et al. (2007) Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. Exp Hematol 35: 1633-1640.
43. Theocharides A, Passweg JR, Medinger M, Looser R, Li S, et al. (2008) The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica 93: 1890-1893.
44. Van Pelt K, Nollet F, Selleslag D, Knoops L, Constantinescu SN, et al. (2008) The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation. Blood 112: 921-922.
45. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, et al. (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351: 657-667.
46. Sloma I, Jiang X, Eaves AC, Eaves CJ, (2010) Insights into the stem cells of chronic myeloid leukemia. Leukemia 24: 1823-1833.
47. Petzer AL, Eaves CJ, Barnett MJ, Eaves AC, (1997) Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 90: 64-69.
48. Dazzi F, Hasserjian R, Gordon MY, Boecklin F, Cotter F, et al. (2000) Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and cell lineage representation. Hematol J 1: 307-315.
49. Jiang X, Saw KM, Eaves A, Eaves C, (2007) Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 99: 680-693.
50. Bumm T, Deininger J, Newell AH, Lawce H, Olson S, et al. (2010) Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors. Leukemia 24: 1525-1528.
51. Schemionek M, Elling C, Steidl U, Baumer N, Hamilton A, et al. (2010) BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 115: 3185-3195.
52. Chu SH, Heiser D, Li L, Kaplan I, Collector M, et al. (2012) FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. Cell Stem Cell 11: 346-358.
53. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH, (2007) Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 129: 1081-1095.
54. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, et al. (2006) PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441: 518-522.
55. Janzen V, Forkert R, Fleming HE, Saito Y, Waring MT, et al. (2006) Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 443: 421-426.
56. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, et al. (2000) Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287: 1804-1808.
57. Degregori J, (2012) Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age? Oncogene 32 (15):: 1869-1875.
58. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, et al. (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360: 2289-2301.
59. Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, et al. (2010) Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 115: 2003-2007.
60. Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, et al. (2006) Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108: 3548-3555.
61. Plo I, Nakatake M, Malivert L, de Villartay JP, Giraudier S, et al. (2008) JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 112: 1402-1412.
62. Zhao R, Follows GA, Beer PA, Scott LM, Huntly BJ, et al. (2008) Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N Engl J Med 359: 2778-2789.
63. Cross NC, (2011) Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011: 208-214.
64. Kent D, Dykstra B, Eaves C, (2007) Isolation and assessment of long-term reconstituting hematopoietic stem cells from adult mouse bone marrow. Curr Protoc Stem Cell Biol Chapter 2: Unit 2A 4.
65. Hu Y, Smyth GK, (2009) ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347: 70-78.